Cyxone, a Swedish biotechnology company, has applied for a Phase II clinical trial for Rabeximod. It is planned that the tests will take place in Poland, Ukraine, Slovakia, and Hungary, as the official website of the company says.
What is Rabeximod?
Rabeximod is an oral drug in development for the treatment of active rheumatoid arthritis (RA). But this is one of the directions.
The second phase of clinical trials will directly concern patients with Covid-19. It is a treatment aimed at reducing the risk of developing severe respiratory symptoms caused by over-activation of the immune system associated with viruses. Most people with Covid-19 experience only mild symptoms, but in severely "affected" patients, the immune system overreacts, causing a disproportionate release of cytokines and chemokines, leading to hyperinflammation and severe respiratory failure.
The Rabeximod drug began to be tested on patients with Covid-19 based on the discovery of the American scientist Dr. Kalev Kask, who discovered the drug's potential to control the overactivation of the immune system in patients infected with life-threatening viruses (for example, Sars-Cov-2).
In parallel, Cyxone continues to develop Rabeximod as a potential treatment for rheumatoid arthritis.
What do we know about Cyxone?
Cyxone AB is a clinical biotech company with a portfolio of immunomodulatory drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).
The company offers two candidate drugs (that is, while research is underway): T20K for the treatment of multiple sclerosis in clinical phase I and Rabeximod for the treatment of RA in the clinical phase II program.
How will the research proceed?
To assess the drug's efficacy, 300 patients suffering from moderate Covid-19 who require oxygen therapy but not ventilated therapy will receive one of two doses of Rabeximod or placebo in a double-blind study.
Cyxone plans to release preliminary research data in the third quarter of 2021.
If the trial is positive, Cyxone intends to apply for an emergency use authorization after identifying a strategic commercialization partner.
In parallel, the company will continue to develop Rabeximod for the treatment of Covid-19, as well as for the treatment of other respiratory diseases caused by viruses and rheumatoid arthritis.
"We are pleased to soon initiate our Phase 2 study in which we aim to develop an oral treatment for moderate Covid-19 patients, preventing the progression to acute symptoms avoiding the need of intensive care treatment and relieving the burden on hospitals and healthcare systems. Given a successful outcome, Rabeximod could be developed as a candidate drug not only for Covid-19, but for the treatment of other disorders of the immune system including virally induced acute respiratory disorders," comments CEO Tara Heitner.